guidelines on variations to a registered pharmaceutical product

More documents

Recommendations

Info

Guidelines on Variations to a Registered Pharmaceutical Product49 Change in any part of the (primary) packaging material not in contact with the finishedpharmaceutical product formulation (e.g. colour of flip-off caps, colour code rings onampoules, change of needle shield)................................................................................... 5550 Change to an administration or measuring device that is not an integral part of theprimary packaging (excluding spacer devices for metered dose inhalers) involving:......... 555.3.2.6 Stability...........................................................................................................................5651 Change in the shelf-life of the finished pharmaceutical product (as packaged for sale)involving:............................................................................................................................. 5652 Change in the in-use period of the finished pharmaceutical product (after first openingor after reconstitution or dilution):........................................................................................ 5653 Change in the labelled storage conditions of the finished pharmaceutical product (aspackaged for sale), the product during the in-use period or the product after reconstitutionor dilution............................................................................................................................. 575.4 Safety and Efficacy changes...................................................................................................585.4.1 Human and Veterinary Pharmaceutical Products.......................................................................5854 Change in the Summary of Product Characteristics, Labelling or Package Leafletfollowing a procedure in accordance with Article 30 or 31 of Directive 2001/83/EC orArticles 34 or 35 of Directive 2001/82/EC (referral procedure)......................................5855 Change in the Summary of product Characteristics, Labelling or Package Leaflet of ageneric/hybrid/biosimilar pharmaceutical product following assessment of the samechange for the reference (innovator) product.................................................................5856 Implementation of change(s) requested by NDA (National Drug Authority) followingassessment of an Urgent safety restriction, class labelling or periodic safety updatereport..............................................................................................................................5957 Variations related to significant modifications of the Summary of ProductCharacteristics due in particular to new quality, pre-clinical, clinical orpharmacovigilance data.................................................................................................5958 Change(s) to therapeutic indication(s)...........................................................................595.4.2 Veterinary Pharmaceutical Products - specific changes.............................................................6059 Variations concerning a change to or addition of a non-food producing targetspecies...........................................................................................................................6060 Deletion of a food producing or non-food producing target species...............................6061 Change to the withdrawal period for a Veterinary pharmaceutical product....................6062 Changes to the labelling or the package leaflet which are not connected with thesummary of product characteristics...............................................................................606. APPENDIX 1: EXAMPLES OF CHANGES THAT MAKE A NEW APPLICATION/EXTENSION APPLICATION NECESSARY............................................................... 617. APPENDIX 2: CHANGES TO EXCIPIENTS.............................................................. 628. LITERATURE REFERENCES.................................................................................... 63Doc. No.: DAR/GDL/005 Revision Date: 8 th July 2013 Review Due Date: 16 th July 2016Revision No.: 1 Effective Date : 16 th July 2013 Page vi of 70
Guidelines on Variations to a Registered Pharmaceutical Product1. INTRODUCTIONNational Drug Authority (NDA) was established in 1993 by the National DrugPolicy and Authority Statute which in 2000 became the National Drug Policy andAuthority (NDP/A) Act, Cap. 206 of the Laws of Uganda (2000 Edition). The Actestablished a National Drug Policy and National Drug Authority to ensure theavailability, at all times, of essential, efficacious and cost-effective drugs to theentire population of Uganda, as a means of providing satisfactory healthcareand safeguarding the appropriate use of drugs.The Vision of NDA: “A world class drug regulatory agency effectively protectingand promoting public health”.The Mission of NDA: “To ensure access to quality, safe and efficacious humanand veterinary medicines and other healthcare products through the regulationand control of their production, importation, distribution and use”.The National Drug Policy and Authority Act, Section 35 mandates NDA toscientifically examine any drug for purposes of ascertaining efficacy, safety andquality of a drug before registration for use in Uganda.A registered Finished Pharmaceutical Product (FPP) supplier is responsible forthe registered FPP throughout its life irrespective of the regular reviews by NDAand is, therefore, required to take into account technical and scientific progress.He or she is required to make any amendment that may be required to enablethe registered FPP to be manufactured and checked by means of generallyaccepted scientific methods. Suppliers of registered FPPs may also wish toalter or to improve the FPP or to introduce an additional safeguard.Regulation of medicinal products (FPPs) is, therefore, considered dynamic,taking into account that changes to the original dossier that was used forregistration of the FPP may become necessary during the lifetime of the product.Any changes to a registered FPP (variations) may involve administrative and/ormore substantial changes and are subject to approval by NDA.Procedures for the implementation of the different types of variations need tobe set out to facilitate the task of both suppliers and NDA and to guarantee thatvariations to the FPP do not give rise to public health concerns.The Guideline is therefore, intended to provide guidance to applicants on theconditions to be fulfilled and the type of documentation to be submitted beforeDoc. No.: DAR/GDL/005 Revision Date: 8 th July 2013 Review Due Date: 16 th July 2016Revision No.: 1 Effective Date : 16 th July 2013 Page 1 of 70
Page 2 and 3: Authorization of these guid
Page 4: Guidelines on Variations to a Regis
Page 9 and 10: Guidelines on Variations to a Regis
Page 55 and 56:
Guidelines on Variations to a Regis
Page 57 and 58:
Page 59 and 60:
Page 61:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
show all

guidelines on variations to a registered pharmaceutical product

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?